Table 2 Clinicopathologic characteristics of all 1396 patients of lymph node negative ER+/HER2- breast cancer with RS < 18 by LRR (all percentages within columns)
|  | No LRR (n = 1383) | LRR (n = 13) |
|---|---|---|
RS | ||
 Mean, median (range) | 12, 12 (0–17) | 11, 12 (0–17) |
 RS 0–10; n (%) | 500 (36.2%) | 5 (38.5%) |
 RS 11–17; n (%) | 883 (63.8%) | 8 (61.5%) |
Age at diagnosis | ||
 Mean, median (range); years | 57, 57 (22–90) | 55, 54 (35–79) |
  < 40 years; n (%) | 61 (4.4%) | 2 (15.4%) |
  40–49 years; n (%) | 328 (23.7%) | 3 (23.1%) |
  ≥ 50 years; n (%) | 994 (71.9%) | 8 (61.5%) |
Tumor size, median (range); cm | 1.31, 1.2 (0.3–5.8) | 1.5, 1.3 (0.5–3.5) |
Multifocality; n (%) | 291 (21%) | 6 (46.2%) |
LVI; n (%) | 262 (18.9%) | 4 (30.8%) |
Local treatment; n (%) | ||
 BCS only | 46 (3.3%) | 2 (15.4%) |
 BCS and radiation therapy | 923 (66.7%) | 7 (53.8%) |
 Total mastectomy | 410 (29.6%) | 4 (30.8%) |
 Total mastectomy and radiation therapyb | 4 (0.3%)b | 0 |
Systemic therapy; n (%) | ||
 Endocrine therapy only | 1176 (85%) | 8 (61.5%) |
 Endocrine therapy and chemotherapya | 165 (11.9%)a | 4 (30.8%) |
 No systemic therapy | 42 (3%) | 1 (7.7%) |
Median follow-up (range); months | 51.9 (0.9–108.3) | 71.4 (43.2–86.8) |
Time to LRR, median (range), months | – | 36.5 (9.7–74.3) |